Original articleOff-Label Use of Antiepileptic Drugs for the Treatment of Neonatal Seizures
Introduction
The treatment of neonatal seizures is often unsatisfactory. Despite evidence from a rigorously conducted clinical trial that the administration of phenobarbital or phenytoin was effective in less than 50% of cases [1], almost a decade later, these drugs remain the most common treatment for neonatal seizures [2]. A recent survey of 5 American neonatal intensive care units showed that anticonvulsant therapy is initiated in over 94% of neonates with seizures, and that phenobarbital is the drug of first choice for 82% [3].
There is a paucity of data regarding the pharmacokinetics of many drugs and interactions among medications in neonates, and “off-label” drug use is very common in this age group [4], [5]. Although neonatologists frequently initiate treatment for neonatal seizures, they often consult pediatric neurologists if seizures recur after the administration of a loading dose of phenobarbital. Over the past decade, several newer antiepileptic drugs have gained wide acceptance in pediatric neurology practice. Anecdotal reports suggest that some of these antiepileptic drugs are being used to treat neonatal seizures. To gain an understanding of this rapidly evolving practice, we surveyed pediatric neurologists about their recommendations for the treatment of neonatal seizures with newer antiepileptic drugs. We hypothesized that 2 drugs, levetiracetam and topiramate, would be recommended more frequently than other newer antiepileptic drugs, and we focused on these agents.
Section snippets
Methods and Results
At the 2007 Annual Meeting of the Child Neurology Society, surveys were distributed at a poster presentation that discussed the treatment of neonatal seizures [6], and at a meeting of the Neonatal Neurology Interest Group. Fifty-five completed surveys were collected. All respondents were pediatric neurologists, and all but one indicated that they consulted in neonatal intensive care units. Forty respondents were in academic practice, 12 were in hospital-based or private practice, and 3 were in
Discussion
Published guidelines for levetiracetam and topiramate in one of the most commonly used pharmacy references, the Micromedex Healthcare Series-Drugdex, reveal that no information is available for levetiracetam regarding its use as an intravenous formulation for children less than 16 years old, and for the oral formulation, no information is available about safety or efficacy for children below age 4 years. For topiramate, the entry states, “Efficacy in seizures not established in children under 2
References (12)
- et al.
Neonatal seizures: Multicenter variability in current treatment practices
Pediatr Neurol
(2007) - et al.
Therapeutic doses of topiramate are not toxic to the developing rat brain
Exp Neurol
(2004) - et al.
Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain
Exp Neurol
(2005) - et al.
Phenobarbital compared with phenytoin for the treatment of neonatal seizures
N Engl J Med
(1999) - et al.
Neonatal seizures: After all these years we still love what doesn't work
Neurology
(2005) - et al.
Unlicensed and off-label medication use in a neonatal intensive care unit: A prospective study
Am J Perinatol
(2002)
Cited by (120)
Neonatal Seizures
2023, Avery's Diseases of the NewbornThe duration of successive epileptic seizures is monotonically correlated in neonates
2022, Neurophysiologie CliniqueDrug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management
2022, Drug Discovery TodayComparative efficacy of anti-epileptic drugs for neonatal seizures: A network meta-analysis
2021, Pediatrics and NeonatologyNovel Therapeutics for Neonatal Seizures
2021, Neurotherapeutics